HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT00581243

Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients

A short description of this study’s research objective has not yet been verified.

Medication studyAges 18–50
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 50 years.

Activities
Medication described in the protocol
Compensation
Payment and expense reimbursement have not been verified.

Registry last updated: · Record retrieved: . These dates do not confirm site availability.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 1, 2008
Recruitment status
Terminated
Enrollment listed in the registry
32
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
Not clearly listed
Age range
From 18 Years to 50 Years
Official registry ID
NCT00581243
Official title
An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SLV-313 Sustained-Release (SR) Tablets Administered Orally to Subjects With Schizophrenia and Schizoaffective Disorder

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT00581243. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Terminated

Locations not listed

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Wyeth is now a wholly owned subsidiary of Pfizer.

Does this study involve medication?

Yes. The study involves medication, including SLV-313 SR.

Who can participate?

Listed age limits: 18 years to 50 years.

Is this study still recruiting?

The registry lists this study as terminated.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.